Understanding Your Diagnosis: An Introduction to Hypertrophic Cardiomyopathy
At a Glance
Hypertrophic Cardiomyopathy (HCM) is a common genetic heart condition where the heart muscle becomes abnormally thick. With modern medical care, most people with HCM live a full, normal lifespan, though close family members should be screened due to the genetic nature of the disease.
Receiving a diagnosis of Hypertrophic Cardiomyopathy (HCM) can feel overwhelming and frightening. It is natural to feel a sense of uncertainty when told you have a “genetic heart condition.” However, it is important to know that while HCM is a lifelong condition, the outlook for most people today is very positive. With modern medical care, the majority of people with HCM live a full, normal lifespan [1][2][3].
This page will help you understand what HCM is, how common it is, and why it affects different people in different ways.
What is Hypertrophic Cardiomyopathy?
At its simplest, Hypertrophic Cardiomyopathy (HCM) is a condition where the muscle of the heart becomes abnormally thick (hypertrophied) [2]. This thickening usually occurs in the left ventricle, which is the heart’s main pumping chamber [4].
When the heart muscle is too thick, it can become “stiff,” making it harder for the heart to fill with blood or pump it out efficiently to the rest of the body [5]. Doctors typically diagnose HCM when the heart wall thickness is 15 millimeters or greater and cannot be explained by other common causes like high blood pressure [2][4].
How Common is HCM?
HCM is far more common than many people realize. It is the most frequent inherited heart disease in the world [1].
- Prevalence: Research suggests that between 1 in 500 (0.2%) and 1 in 200 (0.5%) people in the general population have HCM [1][6].
- Underdiagnosis: Because many people have few or no symptoms, a large number of people living with HCM remain undiagnosed [6].
A Genetic Blueprint
HCM is primarily a genetic condition, meaning it is passed down through families. It is most often caused by mutations in the genes that provide instructions for the proteins that help the heart muscle contract [7][8].
The two most common genes involved are MYBPC3 and MYH7 [9][7]. Because it is inherited, if you have HCM, your first-degree relatives (parents, siblings, and children) have a 50% chance of also carrying the gene mutation. Current guidelines strongly recommend cascade screening, which is the process of testing these close family members [10][11].
Genetic Counseling and Family Planning
Because of the genetic nature of HCM, it is highly recommended to work with a Genetic Counselor. These specialized professionals can help you navigate the emotional impact of a diagnosis, discuss life insurance implications, and explain what a positive test means for your family [11][10].
For patients of childbearing age, family planning is a major consideration:
- Pregnancy is Generally Safe: With proper multidisciplinary care at a specialized center, most women with HCM can have safe and successful pregnancies [1]. However, certain advanced medications, such as cardiac myosin inhibitors, are strictly contraindicated during pregnancy and must be stopped beforehand [12].
- Alternative Planning (IVF/PGT-A): For those who wish to ensure the HCM mutation is not passed to their children, In Vitro Fertilization combined with Preimplantation Genetic Testing for Aneuploidy (IVF/PGT-A) is an option to screen embryos for the known familial mutation [10].
- Screening Children: For kids who are at risk but have not been genetically tested, clinical screening (like an echocardiogram) typically begins around puberty, or earlier if they are participating in competitive sports or have a family history of early-onset disease [10][11].
Why Families Differ
One of the most confusing aspects of HCM is why it looks different in every person, even within the same family. Researchers have found that even family members with the exact same genetic mutation can have very different experiences:
- Variable Expression: One person might have severe thickening and symptoms, while their sibling has very mild thickening and feels perfectly healthy [9][13].
- Contributing Factors: Scientists believe this variability is caused by a mix of other “modifier” genes, environmental factors, and even biological sex [7][8][13].
Understanding your diagnosis is the first step in taking control of your heart health. While the journey with HCM is lifelong, it is one that can be managed successfully with the right care team [10].
Common questions in this guide
Is hypertrophic cardiomyopathy hereditary?
How is hypertrophic cardiomyopathy diagnosed?
What is cascade screening for HCM?
Can I have a safe pregnancy if I have HCM?
Why do some family members with HCM have no symptoms?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my imaging, what is my maximum wall thickness, and does it meet the criteria for a formal HCM diagnosis?
- 2.What specific genetic mutation (if any) was found, and how does this affect the recommendation for screening my first-degree relatives?
- 3.What is my current risk level for sudden cardiac death based on the latest 2024 AHA/ACC guidelines?
- 4.Do I have the 'obstructive' or 'non-obstructive' form of HCM, and how does that change my treatment plan?
- 5.Are there local HCM 'Centers of Excellence' or specialized multidisciplinary programs you recommend for my long-term care?
- 6.Given my age and family planning goals, what are the safest options for pregnancy and screening?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Ommen SR, Ho CY, Asif IM, et al.
Circulation 2024; (149(23)):e1239-e1311 doi:10.1161/CIR.0000000000001250.
PMID: 38718139 - 2
Frequency of misdiagnosis in hypertrophic cardiomyopathy.
Nielsen SK, Rasmussen TB, Hey TM, et al.
European heart journal. Quality of care & clinical outcomes 2025; (11(2)):105-112 doi:10.1093/ehjqcco/qcae031.
PMID: 38664062 - 3
Survival After Myectomy for Obstructive Hypertrophic Cardiomyopathy: What Causes Late Mortality?
Nguyen A, Schaff HV, Nishimura RA, et al.
The Annals of thoracic surgery 2019; (108(3)):723-729 doi:10.1016/j.athoracsur.2019.03.026.
PMID: 30978316 - 4
Cardiology: hypertrophic cardiomyopathy.
, Firth J
Clinical medicine (London, England) 2019; (19(1)):61-63 doi:10.7861/clinmedicine.19-1-61.
PMID: 30651247 - 5
Cardiac pacing in patients with hypertrophic obstructive cardiomyopathy.
Tolosana JM, Trucco E
Global cardiology science & practice 2018; (2018(3)):29 doi:10.21542/gcsp.2018.29.
PMID: 30393641 - 6
Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review.
Gill R, Siddiqui A, Yee B, et al.
Journal of cardiovascular development and disease 2024; (11(9)) doi:10.3390/jcdd11090290.
PMID: 39330348 - 7
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.
Harper AR, Goel A, Grace C, et al.
Nature genetics 2021; (53(2)):135-142 doi:10.1038/s41588-020-00764-0.
PMID: 33495597 - 8
Interplay of Genotype and Substrate Stiffness in Driving the Hypertrophic Cardiomyopathy Phenotype in iPSC-Micro-Heart Muscle Arrays.
Guo J, Jiang H, Oguntuyo K, et al.
Cellular and molecular bioengineering 2021; (14(5)):409-425 doi:10.1007/s12195-021-00684-x.
PMID: 34777601 - 9
Case Report: Genomic and clinical insights into MYBPC3-related hypertrophic cardiomyopathy in Ecuadorian patients: implications for sudden cardiac death risk.
Paz-Cruz E, Guevara-Ramírez P, Tamayo-Trujillo R, et al.
Frontiers in cardiovascular medicine 2025; (12()):1693244 doi:10.3389/fcvm.2025.1693244.
PMID: 41647802 - 10
Image-Based Computational Hemodynamics Analysis of Systolic Obstruction in Hypertrophic Cardiomyopathy.
Fumagalli I, Vitullo P, Vergara C, et al.
Frontiers in physiology 2021; (12()):787082 doi:10.3389/fphys.2021.787082.
PMID: 35069249 - 11
Major Cardiac Events in Patients and Relatives With Hereditary Hypertrophic Cardiomyopathy.
Nielsen SK, Hansen FG, Rasmussen TB, et al.
JACC. Advances 2023; (2(8)):100604 doi:10.1016/j.jacadv.2023.100604.
PMID: 38938358 - 12
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.
Owens AT, Desai M, Wheeler MT, et al.
Journal of the American Heart Association 2024; (13(17)):e033767 doi:10.1161/JAHA.124.033767.
PMID: 39206723 - 13
Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment.
Butters A, Lakdawala NK, Ingles J
Current heart failure reports 2021; (18(5)):264-273 doi:10.1007/s11897-021-00526-x.
PMID: 34478112
This page provides introductory information about Hypertrophic Cardiomyopathy for educational purposes only. It does not replace professional medical advice, and you should always discuss your specific diagnosis, treatment, and screening needs with your cardiologist.
Get notified when new evidence is published on Hypertrophic Cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.